CDKN2A was associated with several cancer-related pathways, including colorectal cancer, endometrial cancer, and pancreatic cancer, while HSD17B1 was enriched in metabolic and signaling pathways, such as galactose metabolism and MAPK signaling. Here, CDKN2A is linked to cancer.